Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole with mFOLFOX6/Bevacizumab in Metastatic Colorectal Cancer
NCT04761614Phase 1Completed
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of riluzole in colorectal cancer (metastatic) (mCRC). Primary endpoint: Dose Limiting Toxicities at 4 weeks. Started Apr 2021; status: completed.
02
Drugs
riluzole
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04761614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761614.